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Abstract
Aim: Investigate the cost and effects of a single-pill versus two- or three pill first-line antiretroviral combinations in reducing
viral load, increasing CD4 counts, and first-line failure rate associated with respective regimens at 6 and 12 months.
Methods: Patients on first-line TDF+3TC+EFV, TDF+FTC+EFV, TruvadaH+EFV or AtriplaH between 1996–2008 were identified
and viral load and CD4 counts measured at baseline, six and twelve months respectively. Factors that independently
predicted treatment failure at six and twelve months were derived using multivariate Cox’s proportional hazard regression
analyses. Use and cost of hospital services were calculated at six and twelve months respectively.
Results: All regimens reduced viral load to below the limit of detection and CD4 counts increased to similar levels at six and
twelve months for all treatment regimens. No statistically significant differences were observed for rate of treatment failure
at six and twelve months. People on AtriplaH generated lower healthcare costs for non-AIDS patients at £5,340 (£5,254 to
£5,426) per patient-semester and £9,821 (£9,719 to £9,924) per patient-year that was £1,344 (95%CI £1,222 to £1,465) less
per patient-semester and £1,954 (95%CI £1,801 to £2,107) less per patient-year compared with TruvadaH+EFV; healthcare
costs for AIDS patients were similar across all regimens.
Conclusion: The single pill regimen is as effective as the two- and three-pill regimens of the same drugs, but if started as
first-line induction therapy there would be a 20% savings on healthcare costs at six and 17% of costs at twelve months
compared with TruvadaH+EFV, that generated the next lowest costs.
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Introduction
Antiretroviral therapy (ART) has undergone remarkable
development since the antiretroviral properties of AZT were first
established in 1987 with the subsequent development of dual- and
triple-therapy. One of the early problems that people living with
HIV (PLHIV) had was the large pill burden associated with triple-
therapy when first introduced into routine treatment and care in
1996. The association of lowered adherence with increased pill
burden and poorer outcomes has been recognized for some time,
in terms of number of pills to be taken and the frequency with
which they have to be taken [1,2].
To reduce pill burden, various strategies have been developed
over time to produce once-daily dose regimens, combining a
number of different drugs into fewer tablets: ‘fixed-dose combi-
nations’ (FDCs). In some FDCs different antiretroviral drugs
(ARVs) are combined into one tablet that can be taken once-a-day
and improves adherence [3–6]. Similar findings have recently
been reported with the use of FDCs in the management of
hypertension [7].
The production of FDCs precedes their development and use
for HIV infection. One of the first FDCs was an oral contraceptive
produced in the 1960s followed by the development of maloprim
(pyrimethamine+dapsone) and cotrimoxazole (trimethoprim+sul-
famethoxazole) in the late 1960’s [8]. In 2002 the WHO Expert
Committee on the Use of Essential Drugs provided the following criteria
for FDCs: ‘‘Most essential medicines should be formulated as single
compounds. Fixed dose combination products are selected only when the
combination has a proven advantage over single compounds administered
separately in therapeutic effect, safety, adherence or in delaying the development
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of drug resistance in malaria, TB and HIV/AIDS.’’ [8]. In addition to
these criteria identified by the WHO Expert Committee,
healthcare costs are now also recognized as an important criterion.
AtriplaH is a FDC currently on the market that combines
Tenofovir (TDF) with Emtracitabine (FTC) and Efavirenz (EFV).
Prior to the introduction of this FDC, TDF was initially prescribed
separately with Lamivudine (3TC) and EFV, while after the
release of FTC on the market, the three pill regimens also included
TDF, FTC and EFV. The next development was a combination of
TDF and FTC into one pill – TruvadaH; subsequently EFV was
added to TruvadaH to create AtriplaH, a single-pill ARV regimen.
TruvadaH+EFV were licensed for first-line induction therapy in
2005 in the UK, while AtriplaH was licensed for first-line therapy
in the US in 2006 and in 2007 in the UK. AtriplaH is currently not
licensed for first-line induction therapy in the UK but clinicians
can switch from TruvadaH+EFV to AtriplaH as part of first-line
simplification. This particular first-line regimen can therefore be
prescribed in four combinations and the aim of this study was to
compare the effectiveness and costs of these four combinations in
terms of reducing viral load, increasing CD4 counts and treatment
failure at 6 and 12 months respectively.
Methods
The National Prospective Monitoring System on the use, cost
and outcome of HIV service provision in UK hospitals - HIV
Health-economics Collaboration (NPMS-HHC) has monitored
prospectively the effectiveness, efficiency, equity and acceptability of
treatment and care in participating HIV units since 1996. Using
an agreed minimum dataset, standardized data are routinely
collected in clinics and transferred to the NPMS-HHC Coordi-
nating and Analytic Centre (CAC) [9]. Since the data were
transferred in pseudo-anonymized format, patient consent was not
required according to the UK Department of Health in line with
international guidelines [10].
Statistical Analyses
Parametric quantitative data are presented as means with 95%
confidence intervals (CIs) or standard deviation (SD) while non-
parametric data are presented as medians with inter-quartile range
(IQR). Between group comparisons of parametric data with more
than two independent groups were tested using one-way-ANOVA
while two independent groups were compared using unpaired t-
test. Between group comparisons of non-parametric data with
more than two independent groups were tested using the Kruskal-
Wallis test while two independent groups were compared using the
Mann-Whitney U test. Qualitative data by CD4 count strata were
tested using the x2 test as well as test for trend and where
appropriate these were adjusted using Yates’ correction.
Clinical Outcomes: CD4 counts and viral load when
starting ART
Baseline CD4 counts and baseline viral loads were obtained
within 4 months before or up to two weeks since starting the first-
line regimens under consideration with the closest value to starting
the regimen taken as baseline. For 7% of cases baseline CD4
counts and for 10% of cases baseline viral loads could not be
obtained and for these patients their baseline CD4 counts or
baseline viral loads were imputed using the Multiple Imputations
(MI) procedure in SAS. This procedure assumes that the missing
baseline CD4 count and baseline viral load data were missing at
random (MAR). The missing baseline CD4 counts and baseline
viral loads were substituted with an estimated value using a
multiple imputation procedure which replaced each missing value
with a set of plausible values that represented the uncertainty
about the right value to impute [11]. The Markov Chain Monte
Carlo (MCMC) method was used to predict mean matching
method for imputation, a method that assumed multivariate
normality [12]. The MCMC method imputed an observed value
that was nearest to the predicted value from the simulated
regression model for each missing value imputed.
Longitudinal changes in CD4 count
Linear mixed models were used to calculate the difference in
averages (DAVG) which represent the time weighted difference in
CD4 counts from baseline to clinic visits at 6 and 12 months
respectively, and where necessary data were transformed to
stabilize the variance.
MIXED procedure in SAS was used to fit values of all available
CD4 count results since starting first line regimen as a dependent
variable. Independent variables included the fixed effects of the
treatment groups TDF+3TC+EFV, TDF+FTC+EFV, TruvadaH
+EFV or AtriplaH, clinic visit time points at 6 and 12 months, and
treatment groups by study time point interaction. A covariance
matrix was used to model the within patient errors. Estimates of
change in CD4 count from baseline were obtained from
intervention by clinic visit time point interaction. Trends over
time are presented as point estimates with 95% confidence
intervals (CIs). Multivariable analyses presented were adjusted for
other time varying co-variables assumed to have potential
confounding or residual effect on the trend of CD4 count changes,
including baseline age, sex, ethnic group, clinical status, log10 viral
load (VL) and year of starting ART.
Time to first line treatment failure
Time to first-line treatment failure was estimated from the date
of starting the first-line regimen. First-line treatment failure was
defined as any change to treatment, this included intensification of
regimen by further adding anti-retroviral drug to the regimen or
swapping to another anti-retroviral drug class. Simplification of
ARVs with no other changes made to the regimen did not
constitute treatment failure. Causes of treatment failure included
clinical, immunological or virological reasons and others, where
adverse effects were the most likely cause [13]. Event time was
defined as time from starting first-line treatment until the end of
the study periods at 6 or 12 months respectively, or the date of
failing first-line TDF+3TC+EFV, TDF+FTC+EFV, TruvadaH
+EFV or AtriplaH before 6 or 12 months respectively. Data were
censored either at the end of study period, the date of last clinic
visit or date of death if patients had died during the 6 or 12 months
study periods. Where patients were on treatments for longer than
the study periods at 6 or 12 months, then data were censored at
the last date of each respective study periods. Survival curves for
overall duration of treatment failure were plotted according to the
Kaplan-Meier method and the log-rank method was used to test
for differences in survival distributions [14].
Cox’s proportional hazards regression models with single
variables were initially used to estimate likelihood of treatment
failure. All variables found to have a probability of p,0.2 in
univariable Cox’s proportional hazards model were used to build a
multivariable model to determine independent predictors of
treatment failure while controlling for the other variables in the
model. Quantitative data were categorised using median and
inter-quartile ranges (IQR), including a separate category for any
variables with missing data. This ensured no degrees of freedom
were lost when building the multivariable models. The final
multivariable models presented were tested for their distributional
assumptions using Cox Snell residual plots and adjusted for sex,
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age, ethnic group, baseline CD4 count and viral load, stage of
HIV infection at start of treatment and year of starting ART.
Use and cost of services
Data on the use of hospital inpatient, outpatient and dayward
services between 1st January 2004 and 31st December 2008 were
obtained from computerized information systems from 9 UK
hospitals participating in this analysis. All patients who started on
first line TDF+3TC+EFV, TDF+FTC+EFV, TruvadaH+EFV or
AtriplaH during that period were identified and patients who were
known to have transferred from other HIV units were excluded as
it was not possible to establish with certainty whether these
regimens were indeed their first-line regimen.
The mean number of inpatient days, outpatient visits and
dayward visits were calculated for the first six and twelve months
on ART respectively. The denominator for those on first-line
TDF+3TC+EFV, TDF+FTC+EFV, TruvadaH+EFV or AtriplaH
consisted of the total duration of follow up from when these first-
line regimens were started until the end of 6 or 12 months
respectively and data were censored as described above. Analyses
were stratified by treatment regimens and whether patients had
had an AIDS diagnosis or not.
Numerators were calculated by summing the use of inpatient,
outpatient or dayward services while on these first-line regimens.
Mean use of services and 95% confidence intervals (95%CI) were
calculated per patient-semester (6 months) and patient-year (12
months) and summarized by the formula:
M~
Pn
i~1
Pk
j~1
Sij
Pn
i~1
Pk
j~1
(tij{ti(j{1))
X183(6months)orX365:25(12months)
Where
n = total number of individuals;
k = day of censoring;
Sij = use of service of individual i at jth day;
tij = number of days on first-line TDF+3TC+EFV,
TDF+FTC+EFV, TruvadaH+EFV or AtriplaH for
individual i;
M = mean of services at i) 6 months or ii) 12 months
The method used to calculate mean use of services has been
employed in a large number of previously published studies [15–
18]. It is based on a standardized approach that was developed
within an European Union Action to analyze HIV healthcare
resource utilization across Europe [19,20] and subsequently
adopted by other European Union Concerted Actions [21]. While
some would propose assigning mean costs weights to resources
used at the individual patient level, this increases the skewing effect
Table 2. CD4 T-cell count changes at 6 and 12months for non-AIDS and AIDS patients on different first-line regimens.
Mean (95% CI) increase in CD4 T-cell count from baseline cells/mm3
AtriplaH TruvadaH+EFV TDF+FTC+EFV TDF+3TC+EFV
6 months 12 months 6 months 12 months 6 months 12 months 6 months 12 months
Total = 1122 N=681 N=248 N=64 N=129
Non-AIDS 95 (82 to
108)
156 (138 to
174)
95 (74 to 117) 161 (134 to
187)
94 (46 to 142) 153 (102 to
203)
111 (82 to 139) 145 (109 to
181)
Total = 326 N=168 N=78 N=18 N=62
AIDS 105 (82 to
128)
158 (124 to
191)
87 (53 to 122) 171 (128 to
213)
105 (1 to 215) 188 (1 to
407)
104 (59 to 149) 145 (89 to
201)
doi:10.1371/journal.pone.0047376.t002
Figure 1. Change in CD4 count from baseline for non-AIDS patients at 6 months for the four treatment regimens.
doi:10.1371/journal.pone.0047376.g001
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of individual outliers and thereby increase the variability of the
results. While this may be of interests, the standardized method
adopted considered that policy makers are better served with
tighter cost-estimates with less of a focus on variability.
The unit cost for an average inpatient day was £511, £101 for
an outpatient visit and £413 per dayward visit, unit costs that were
obtained from the 2010 NPMS-HHC report [22]. Inpatient,
outpatient and dayward costs were obtained by multiplying their
means and 95% CIs by their respective unit costs. The costs
generated by the use of services were added to the costs of
TDF+3TC+EFV, TDF+FTC+EFV, TruvadaH+EFV or AtriplaH,
‘other’ drugs, and tests and procedures performed. Separate
analyses will be presented for those PLHIV who had developed
AIDS and those who had not (non-AIDS). The costs for the
different ART regimens were prices negotiated by the London
HIV Consortium in 2008 with pharmaceutical companies. During
2008 London ARV prices were on average 9% below out-of-
London prices, but the latter have since decreased to come in line
with London prices (Peter Sharott, personal communication 2011).
Furthermore, the costs for ‘other’ drugs, tests and procedures were
weighted by stage of HIV infection: non-AIDS or AIDS. The
study was performed from a public service perspective [15] and
costs for, ‘other’ drugs, tests and procedures performed, were also
obtained from the 2010 NPMS-HHC report [22]. Costs were
calculated in UK pounds (2008 prices) but not discounted given
the short study periods of six and twelve months respectively. All
analyses were performed using SAS version 9.1.3 statistical
software and all significance tests presented are two-tailed.
Results
The total number of patients who started on the four regimens
was 1,448, of whom 25% had been diagnosed with AIDS (Table 1).
Among both groups of patients, the largest proportion had been
started on AtriplaH, followed by TruvadaH+Efavirenz,
TDF+3TC+EFV and least number of patients started on
TDF+FTC+EFV.
No significant differences were observed in terms of age when
starting first-line ART, sex and past or current history of injecting
drugs for patients starting on the different regimens. Some minor
Figure 2. Change in CD4 count from baseline for non-AIDS patients at 12 months for the four treatment regimens.
doi:10.1371/journal.pone.0047376.g002
Figure 3. Change in CD4 count from baseline for AIDS patients at 6 months for the four treatment regimens.
doi:10.1371/journal.pone.0047376.g003
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differences were noted among the ethnic background of AIDS
patients (Table 1).
Viral load and CD4 count at 6 and 12 months induction
ART
Baseline viral loads for non-AIDS patients on AtriplaH were
significantly lower than for those patients on the other regimens
(Table 1). However the median VL for all non-AIDS patients had
become undetectable at 6 months at less than 50 copies/ml (IQR
,50 and ,50 copies/ml) and this was still the case at 12 months.
Mean CD4 count for all non-AIDS patients starting ART was
,350 cell/mm3, with baseline CD4 count for patients on AtriplaH
significantly higher than that for other regimens; baseline CD4
counts for the other three regimens were similar (Table 1).
Increases in mean CD4 count at 6 months were, however, similar
across all four regimens (Table 2; Figure 1) as were mean increases
at 12 months (Table 2; Figure 2).
Baseline viral loads for AIDS patients on AtriplaH were
significantly lower than for those patients on other regimens
(Table 1). However, median viral load for all AIDS patients at 6
months had become undetectable at less than 50 copies/ml (IQR
,50 and ,50 copies/ml) and remained undetectable at 12
months. Mean baseline CD4 count for AIDS patients were all less
than 250 cells/mm3, with TDF+3TC+EFV patients having the
lowest CD4 count (Table 1); increases in CD4 counts were similar
for all AIDS patients at 6 (Table 2; Figure 3) and 12 months after
starting all ART regimen (Table 2; Figure 4).
Treatment Failure at 6 and 12 months
No significant statistical differences were observed between
regimens in terms of likelihood of treatment failure at 6 and 12
months (Tables 3 and 4).
Use and cost of services
For non-AIDS patients, the cost of use of services at 6 months
ranged from £5,340 (95%CI £5,254 to £5,426) for those on
AtriplaH to £7,554 (95%CI £7,243 to £7,864) for those on
TDF+3TC+EFV. Patients on AtriplaH generated the lowest cost,
as their use of inpatient services was significantly lower than that
generated by patients on the other regimens. For TruvadaH+EFV
the cost of services at 6 months was £6,684 (95%CI £6,476 to
£6,891) which was £1,344 (95%CI £1,222 to £1,465) per
patient-semester more expensive compared with AtriplaH
(Table 5).
By twelve months, annual cost per patient-year for non-AIDS
patients ranged from £9,821 (95%CI £9,719 to £9,924) for
patients on AtriplaH to £13,467 (95%CI £13,075 to £13,860) per
patient-year for patients on TDF+3TC+EFV. For TruvadaH+EFV
the cost of services at 12 months was £11,775 (95%CI £11,520 to
£12,031) which was £1,954 (95%CI £1,801 to £2,107) per
Figure 4. Change in CD4 count from baseline for AIDS patients at 12 months for the four treatment regimens.
doi:10.1371/journal.pone.0047376.g004
Table 3. Multivariable Cox’s proportional hazards regression model showing likelihood of first line treatment failure for the four
treatment combinations at 6 months.
Variable Total started first line HAART
Rx failure at 6
months Hazard Ratio* 95% CI p-value
N=1448 n=176 (%)
ART at TDF+FTC+EFV 82 10 (12.2%) 0.97 (0.37 to 2.54) 0.945
start of 1st TDF+3TC+EFV 191 32 (16.8%) 0.74 (0.24 to 2.30) 0.608
line TruvadaH+EFV 326 35 (10.7%) 0.74 (0.33 to 1.65) 0.459
HAART AtriplaH 849 99 (11.7%) 1
*Adjusted for sex, age, ethnic group, baseline CD4 count, baseline viral load, stage of HIV at start of ART and year of starting first-line ART.
doi:10.1371/journal.pone.0047376.t003
Lower Healthcare Costs and Single-Pill FDCs
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patient-year more expensive compared with AtriplaH (Table 5).
Again the main difference was the reduced use of inpatient services
of those on AtriplaH compared with the other regimens.
For AIDS patients at 6 months, cost of services ranged from
£9,123 (95%CI £8,782 to £9,465) for TDF+FTC+EFV to
£15,061 (95%CI £14,360 to £15,762) for those on
TDF+3TC+EFV. The cost at 6 months for AtriplaH was
£10,836 (95%CI £10,563 to £11,110) and the difference with
TruvadaH+EFV was only £489 (95% £321 to £655) per semester
(Table 6).
At 12 months, the cost per AIDS patient-year ranged from
£17,710 (95% CI £17,281 to £18,139) for those on
TDF+FTC+EFV to £25,811 (95% CI £24,930 to £26,692) per
patient-year for patients on TDF+3TC+EFV. The annual cost on
AtriplaH was £19,933 (95% CI £19,597 to £20,268) and differed
by £328 (95% CI 146 to 512) per patient-year with the
TruvadaH+EFV regimen (Table 6).
Discussion
All regimens displayed similar effectiveness in terms of reducing
viral load to undetectable serum levels by 6 months and
maintained that at 12 months; all regimens increased CD4 count
to similar levels by 6 and 12 months and no statistically significant
differences were observed in terms of treatment failure rates at 6
months and 12. These outcome were achieved, despite that
median VL was lower and mean baseline CD4 counts for non-
AIDS patients on Atripla were higher than for those on other
regimens. While the number of patients failing their regimen was
similar across all regimens, those on Atripla used fewer inpatient or
dayward services. The observed percentage of patients failing
Atripla within one year was 16% and this was similar to the 20%
recently reported from a single London centre [23]. Authors from
that study indicated that most patients had stopped AtriplaH due to
central nervous system adverse events.
In term of use and cost of services for non-AIDS patients,
AtriplaH generated the lowest healthcare costs at six and twelve
months whereas six monthly or annual costs for AIDS patients
were similar across all regimens. Starting with higher CD4 counts,
not using inpatient services, even for those who failed, and using
fewer dayward services, all contributed to lower healthcare costs.
The lowest costs among AIDS patients were generated by patient
on TDF+FTC+EFV. However, as there were only 18 patients on
this regimen - none of whom used inpatient services – questions
can be raised concerning the representative nature of this and the
other results observed among the AIDS patients. Furthermore
waiting until a person living with HIV develops an AIDS defining
condition before starting them on ART would be inappropriate;
one wants to diagnose people living with HIV early and review
them regularly in a controlled clinical situation and start ART well
before they develop AIDS [24]. While some guidelines still
recommend starting ART when CD4 count #350 cells/mm3
[25], recent US guidelines recommend starting when CD4 #500
cells/mm3, while some US clinicians recommend to start ART
when people are diagnosed with HIV irrespective of CD4 count
[26].
The analyses as presented have their limitations. Firstly, some of
the comparator groups had small number of patients many of
whom were seen in London clinics. Secondly first viral load or
CD4 count when starting these regimens could not be retrieved for
a small number of subjects and these had to have their viral load
and CD4 count imputed. Thirdly, the data available for
operational research are by definition observational data [27]
and while the analyses were stratified for potential confounders,
some residual confounding may have remained and affected the
results. However, despite the inherent potential problem associ-
ated with observational data, if one wants to analyze ‘real-life’
service provision or programmes, by necessity one has to rely on
observational data [27].
The report of a 2003 WHO meeting on Fixed-Dose Combinations
for HIV/AIDS, Tuberculosis, and Malaria not only provided evidence
of the effectiveness of generic FDCs against HIV but also tried to
place the role of FDCs within the broader context of diverse
pharmacological interventions [8]. A number of studies have
demonstrated the effectiveness of FDCs in resource limited
situations [28–29] partly through the improved adherence
observed with a single pill [30]. The improvement in adherence
subsequent to the use of a single pill regimen has also been
demonstrated in high-income countries [31–33]. Two recent US
studies demonstrated that the optimum use of single pill regimens
also lowered healthcare costs [32,33] and a recent Italian study
demonstrated the cost-effectiveness of a single pill regimen [34].
Optimizing drug regimens is one of the five pillars of WHO and
UNAIDS’ Treatment 2.0 policy, and includes ‘‘reducing pill burden by
developing ‘one pill a day’ (or less often) fixed-dose combinations (FDCs)’’
and its 2020 Goal is the availability of ‘‘effective, affordable, one pill,
once-daily potent ARV regimens with minimal toxicities or drug interactions
and high barriers to resistance are available in lower and middle-income
countries’’ [35]. Apart from improving long-term adherence,
especially as the number of older people living with HIV are
increasing, the use of such FDC may also reduce the cost of
treatment and care in these resource-limited countries though this
will have to be demonstrated [36,37].
During times when Governments in high-income countries are
also cutting health and welfare budgets to ameliorate rising
healthcare costs [38], healthcare interventions need to be assessed
Table 4. Multivariable Cox’s proportional hazards regression model showing likelihood of first line treatment failure for the four
treatment combinations at 12 months.
Variable Total started first line HAART
Rx failure at 12
months Hazard Ratio* 95% CI p-value
N=1448 n=261 (%)
ART at TDF+FTC+EFV 82 16 (19.5%) 0.98 (0.39 to 2.45) 0.963
start of 1st TDF+3TC+EFV 191 53 (27.8%) 1.41 (0.64 to 3.11) 0.389
line TruvadaH+EFV 326 56 (17.2%) 0.94 (0.48 to 1.85) 0.855
HAART AtriplaH 849 136 (16.0%) 1
*Adjusted for sex, age, ethnic group, baseline CD4 count, baseline viral load, stage of HIV at start of ART and year of starting first-line ART.
doi:10.1371/journal.pone.0047376.t004
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in terms of the cost of the regimen as well as their effectiveness. If it is
considered to be appropriate to start a person living with HIV on a
regimen of TDF, FTC and EFV, strong clinical and financial
arguments can be made for starting this person on single-pill
AtriplaH as first-line therapy. While AtriplaH is currently not
licensed for induction therapy in the UK, a substantial number of
UK clinicians have started using AtriplaH as first-line induction
therapy. If AtriplaH is started as induction therapy, this avoids the
extra costs associated with first starting patients with TruvadaH
+EFV as induction therapy and only switching to AtriplaH after 6
months as part of treatment simplification.
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